European Therapeutic Monoclonal Antibody Markets

Frost & Sullivan, August 2008, Pages: 81

This research service analyses the market landscape, revenue potential, market dynamics and trends in the monocloanl antibodies market focussing on five major markets in Europe. It analyses five major therapeutic areas where these antibodies find its applications. Together it recommends strategies for the players in these markets to obtain best results in the European market.

This Frost & Sullivan research service titled European Therapeutic Monoclonal Antibody Markets provides an overview of therapeutic monoclonal antibodies together with revenues for each therapy area. The research offers a complete analysis of key drivers, restraints and trends in the market. Finally, it provides strategic solutions to the vendors to gain advantage in this growing market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following therapeutic monoclonal antibody (mAbs) markets: oncology, auto immune and inflammatory disorders, organ transplant, infectious diseases and cardio vascular diseases.

Market Overview

mAbs Market Holds Both Promise and Pitfalls

The European therapeutic mAbs markets are growing, driven mainly by the sales of the top five drugs, which constitute about 90 per cent of revenues. The success of these drugs is encouraging companies to invest in this market in a quest to leverage long-term growth opportunities. However, prospective entrants should also take into account other mAbs, which make minimal contribution to overall market revenues. As mAbs are insulated from generics, competition is likely to be within the mAbs market itself and from competing therapies like small molecule drugs. With expanding indications and therapeutic applications, companies should focus on areas that will yield them long-term revenues. Effective strategic focus will enable companies to streamline their research investments and maximise returns.

"A strong R&D pipeline along with expanding applications of mAbs in new therapeutic and disease areas will accelerate market growth," notes the analyst of this research. "The increasing number of alliances between pharma and biotech companies will advance research and technological initiatives, a factor that is key to the continued expansion of the market." The financial success stories of top mAbs drugs have attracted many companies and have resulted in mAbs being identified as a key growth driver in the market. Companies are relying on research to develop mAbs as well as technology associated with it for commercial opportunities. Although issues like high therapy costs and drug format limitations persist, the popularity of mAbs is on the rise. Physicians are increasingly adopting mAbs because of its superior side effect profile. Moreover, continued research will yield innovative products and support growth momentum in the market.

High Costs Threaten to Dampen Market Potential

Two key challenges threaten to derail market prospects. Firstly, the public healthcare system is under tremendous pressure to support the therapy cost of mAbs. However, due to their high costs, the target population for treatment is likely to be limited. Moreover, the inherent challenges associated with development and manufacturing of mAbs is likely to remain high over the long term, which will dampen market growth. "High treatment costs and inherent limitations in the antibody format are constraining market expansion," explains the analyst. "Further, the heightened focus on small molecule drugs will challenge the growth of this market over the next five to seven years."

Investing in research and moving manufacturing units to cheaper destinations will help overcome the high development costs associated with mAbs. Building a recognisable brand will enable companies to popularise mAbs and reduce the risk posed by alternate therapies in the future.
Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following application areas in this research:

- Oncology
- Auto immune and inflammatory disorders
- Organ transplant
- Infectious diseases
- Cardio vascular diseases

1 EXECUTIVE SUMMARY
-Summary of the European Therapeutic Monoclonal Antibody Market
--Overview of the European Therapeutic Monoclonal Antibody Market

2 GLOSSARY OF TERMS
-Abbreviations

3 INDUSTRY CHALLENGES
-Key Industry Challenges
--Identification of Key Issues and Challenges Faced by the Industry

4 EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODY MARKET
-Overview of the European Therapeutic Monoclonal Antibody Market
--Market Overview
--Scope and Segmentation
--Research Methodology
-Market Engineering Measurements
--Market Engineering Measurements
-Market Dynamics
--Market Drivers
--Market Restraints
-Revenue Forecasts
--Revenue Forecasts for the Total European Market
-Market Trends
--Technology Trends
--Product Trends
-Competitive Structure
--Competitive Structure
--Market Share Analysis

5 EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODY MARKET FOR USE IN CANCER
-Forecasts for the European Oncology Therapeutic Monoclonal Antibody Market
--Market Overview
--Market Engineering Measurements
--Currently Marketed Products
--Revenue Forecasts
--R&D Pipeline
--Competition

6 EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODY MARKET FOR USE IN AUTOIMMUNE AND INFLAMMATORY DISEASES
-Forecast for the European Autoimmune and Inflammatory Disease Therapeutic Monoclonal Antibody Market
--Market Overview
--Market Engineering Measurements
--Currently Marketed Products
--Revenue Forecasts
--R&D Pipeline
--Competition

7 EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODY MARKET FOR USE IN ORGAN TRANSPLANT
-Forecast for the European Organ Transplant Therapeutic Monoclonal Antibody Market
--Market Overview
--Market Engineering Measurements
--Currently Marketed Products
--Revenue Forecasts
--R&D Pipeline
--Competition

8 EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODY MARKET FOR USE IN CARDIOVASCULAR DISORDERS
-Forecast for the European Cardiovascular Therapeutic Monoclonal Antibody Market
--Market Overview
--Market Engineering Measurements
--Currently Marketed Products
--Revenue Forecasts
--R&D Pipeline
--Competition

9 EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODY MARKET FOR USE IN INFECTIOUS DISEASES
-Forecast for the European Infectious DiseasesTherapeutic Monoclonal Antibody Market
--Market Overview
--Market Engineering Measurements
--Currently Marketed Products
--Revenue Forecasts
--R&D Pipeline
--Competition

10 MARKET ENGINEERING STRATEGIC RECOMMENDATIONS
-Strategic Recommendations
--Strategic Recommendations for the European Therapeutic Monoclonal Antibody Market

11 DATABASE OF KEY INDUSTRY PARTICIPANTS
-Key Industry Participants in the Market
--Key Industry Participants

12 DECISION SUPPORT DATABASES
-Decision Support Databases for the Industry Participants
--Government Healthcare Expenditure
--Private Healthcare Expenditure
--Pharma R&D Expenditure
--Breast Cancer Incidence
--Colon Rectum Cancer Incidence

List of Figures

Chapter 3

Therapeutic Monoclonal Antibody Market: Key Industry Challenges (Europe), 2008-2014

Chapter 4

Therapeutic Monoclonal Antibody Market: Market Drivers Ranked in Order of Impact (Europe), 2008-2014
Therapeutic Monoclonal Antibody Market: Market Restraints Ranked in Order of Impact (Europe), 2008-2014
Total Therapeutic Monoclonal Antibody Market: Revenue Forecasts (Europe), 2004-2014
Therapeutic Monoclonal Antibody Market: Competitive Structure (Europe), 2007
Therapeutic Monoclonal Antibody Market: Market Share Trends of Major Market Participants (Europe), 2007

Chapter 5

Oncology Therapeutic Monoclonal Antibody Market: Currently Marketed Products (Europe), 2007
Oncology Therapeutic Monoclonal Antibody Market: Revenue Forecasts (Europe), 2004-2014
Oncology Therapeutic Monoclonal Antibody Market: Anti-neoplastic Agent Pipeline Drugs in Phase III (Europe), 2007

Chapter 6

Autoimmune and Inflammatory Disease Therapeutic Monoclonal Antibody Market: Currently Marketed Products (Europe), 2007
Autoimmune and Inflammatory Disease Therapeutic Monoclonal Antibody Market: Revenue Forecasts (Europe), 2004-2014
Autoimmune and Inflammatory Disease Therapeutic Monoclonal Antibody Market: Anti-neoplastic Agent Pipeline Drugs in Phase III (Europe), 2007

Chapter 7

Organ Transplant Therapeutics Monoclonal Antibody Market: Currently Marketed Products (Europe), 2007
Organ Transplant Therapeutics Monoclonal Antibody Market: Revenue Forecasts (Europe), 2004-2014

Chapter 8

Cardiovascular Disorders Therapeutics Monoclonal Antibody Market: Currently Marketed Products (Europe), 2007
Cardiovascular Disorders Therapeutics Monoclonal Antibody Market: Revenue Forecasts (Europe), 2004-2014

Chapter 9

Infectious Diseases Therapeutics Monoclonal Antibody Market: Currently Marketed Products (Europe), 2007
Infectious Diseases Therapeutics Monoclonal Antibody Market: Revenue Forecasts (Europe), 2004-2014
Infectious Diseases Therapeutics Monoclonal Antibody Market: Anti-infective Agent Pipeline Drugs in Phase III (Europe), 2007

Chapter 12

Decision Support Database: Government Healthcare Expenditure in Billion USD (World), 2002-2012
Decision Support Database: Private Healthcare Expenditure in Billion USD (World), 2002-2012
Decision Support Database: Pharmaceutical R&D Expenditure in Million USD (World), 2002-2012
Decision Support Database: Breast Cancer Incidence in '000 (World), 2002-2012
Decision Support Database: Colon Rectum Cancer Incidence in '000 (World), 2002-2012
Therapeutic Monoclonal Antibody Market: Key Industry Challenges (Europe), 2008-2014

Customers who bought this item also bought

• The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
• Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects
• Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
• Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs
• The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
• The Future of the Biologicals Market: Market overview, innovations and company profiles
• Opportunities for Monoclonal Antibodies: Where Companies Are Spending Their Antibody Dollars
• Next-Generation Protein and Peptide Therapeutics
• Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
• Monoclonal Antibody Based Products - Global Strategic Business Report